Priyanka Sharma, MD, has been named vice chair of SWOG’s Breast Committee. Formerly known as the Southwest Oncology Group, SWOG is a global cancer research community and 1 of 5 National Cancer Institute (NCI) National Clinical Trials Network-funded groups.
Priyanka Sharma, MD
Priyanka Sharma, MD
Priyanka Sharma, MD, has been named vice chair of SWOG’s Breast Committee. Formerly known as the Southwest Oncology Group, SWOG is a global cancer research community and 1 of 5 National Cancer Institute (NCI) National Clinical Trials Network-funded groups.
Sharma is an associate professor of medicine and a breast cancer medical oncologist at the University of Kansas Cancer Center, with an interest in both clinical and translational research. She has also been a committed member of SWOG’s Breast Committee since 2013.
“I am deeply privileged and delighted to be given this opportunity. In this position, I hope to continue to foster the development of high-impact research to inform clinical practice,” Sharma said in statement.
She has been the principle investigator of multiple investigator initiated phase I and II clinical trials of novel targeted agents in triple-negative breast cancer (TNBC). Additionally, she headed a regional multisite prospective TNBC registry, which has enrolled 500 participants from the Kansas City Metropolitan area. Her work has awarded her an institutional career development grant from the department of medicine at the University of Kansas and pilot grants from both the National Institutes of Health Clinical and Translational Science Awards and the University of Kansas Cancer Center for clinical and translational research in TNBC.
“Dr. Sharma has been a pioneer in deepening our understanding of triple-negative breast cancer. Her intense, focused approach will be a great asset to SWOG,” Roy Jensen, MD, KU Cancer Center director, said in a statement.
In addition to her new vice chair role with SWOG, Sharma will continue co-leading a project funded by the SWOG Integrated Translational Science Center program. The program seeks to facilitate the incorporation of translational science into NCI-supported cancer clinical trials. She has served with additional organizations including the University of Kansas Cancer Center’s Breast Cancer Disease Working Group. She was also on the institutional review board and the internal advisory board of the University of Kansas Cancer Center Biostatistics and Informatics Shared Resources.
Sharma received her medical degree from the University of Baroda Medical College in Gujarat, India in 1997. She later completed her residency in internal medicine and the fellowship in hematology oncology at the University of Kansas School of Medicine.
UGT1A1 Status Underutilized in Predicting Sacituzumab Toxicity in MBC
April 8th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the value of testing for UGT1A1 status in patients receiving sacituzumab govitecan for hormone receptor–positive breast cancer in the second article of a 2-part series.
Read More
Survival and Safety Outcomes Factor into Use of Sacituzumab Govitecan in HR+ Breast Cancer
March 29th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor–positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Experts Warn of Radiation Overtreatment in Older Women With Early-Stage Breast Cancer
March 20th 2024Studies have found that omitting radiation therapy after breast-conserving surgery and/or omitting axillary surgery in women age 70 years or older does not affect their survival when taking endocrine therapy.
Read More
Analyzing ADC Treatment Sequencing in Advanced Breast Cancer
March 15th 2024In the first article of a 2-part series, Virginia G. Kaklamani, MD, discussed her approach to biomarker testing and treatment sequencing for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Read More